Quality Assurance is of Tremendous Importance in Pharma and Health care sector.
A brief of that is try to explain here..
A Trust of the Customer on Product is solely based on the Effective QA
Process Validation is Key important factor for the Pharmaceutical Industry to maintain Consistent Quality in product which claimed by the manufacturer.
Good Manufacturing Practice (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.
Quality Assurance is of Tremendous Importance in Pharma and Health care sector.
A brief of that is try to explain here..
A Trust of the Customer on Product is solely based on the Effective QA
Process Validation is Key important factor for the Pharmaceutical Industry to maintain Consistent Quality in product which claimed by the manufacturer.
Good Manufacturing Practice (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards. It is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.
Quality Risk management in pharmaceutical Industry. A general Review on Risk analysis and Risk assessment in pharmaceutical Industry as it is prescribed by GMP regulations of WHO, ICH, FDA.
QUALIFICATION & VALIDATION.Validation is an essential part of GMP, and an element of QA.Critical steps in the process need to be validated.Need for confidence that the product will consistently meet predetermined specifications and attributes.
Quality control measures in pharmaceutical industryChemOnTheGo
QUALITY CONTROL
ROLE OF QUALITY CONTROL IN PHARMACEUTICAL INDUSTRY
OBJECTIVES OF QUALITY CONTROL
STEPS IN QUALITY CONTROL
COST OF QUALITY CONTROL
TOTAL QUALITY MANAGEMENT
QUALITY CIRCLE
WHO Good Manufacturing Practice Requirements
Good Manufacturing Practice is the part of quality assurance that ensures that products are consistently manufactured and controlled to the quality standards appropriate to their intended use.
Definition
Scope of calibration
Scope of validation
Frequency of calibration
Importance/ purpose of calibration
Importance/ advantages of validation
Difference between calibration & validation
Validation: Validation is a documented program that provides high degree of assurance that a specific process, method or system consistently produces a result meeting pre-determined acceptance criteria.
Introduction, Regulatory requirements for validation, Role of FDA, Code of Federal regulation, Validation life cycle, Significance of validation, Types of validation, Process valiadation, Phases of process validation, Process capability design, Process Qualification, Validation maintainance phase
Types of Process validation, Examples
The pharmaceutical Quality by Design (QbD) is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based sound science and quality risk management.
Quality Risk management in pharmaceutical Industry. A general Review on Risk analysis and Risk assessment in pharmaceutical Industry as it is prescribed by GMP regulations of WHO, ICH, FDA.
QUALIFICATION & VALIDATION.Validation is an essential part of GMP, and an element of QA.Critical steps in the process need to be validated.Need for confidence that the product will consistently meet predetermined specifications and attributes.
Quality control measures in pharmaceutical industryChemOnTheGo
QUALITY CONTROL
ROLE OF QUALITY CONTROL IN PHARMACEUTICAL INDUSTRY
OBJECTIVES OF QUALITY CONTROL
STEPS IN QUALITY CONTROL
COST OF QUALITY CONTROL
TOTAL QUALITY MANAGEMENT
QUALITY CIRCLE
WHO Good Manufacturing Practice Requirements
Good Manufacturing Practice is the part of quality assurance that ensures that products are consistently manufactured and controlled to the quality standards appropriate to their intended use.
Definition
Scope of calibration
Scope of validation
Frequency of calibration
Importance/ purpose of calibration
Importance/ advantages of validation
Difference between calibration & validation
Validation: Validation is a documented program that provides high degree of assurance that a specific process, method or system consistently produces a result meeting pre-determined acceptance criteria.
Introduction, Regulatory requirements for validation, Role of FDA, Code of Federal regulation, Validation life cycle, Significance of validation, Types of validation, Process valiadation, Phases of process validation, Process capability design, Process Qualification, Validation maintainance phase
Types of Process validation, Examples
The pharmaceutical Quality by Design (QbD) is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based sound science and quality risk management.
Institute of Good Manufacturing Practices India, registered as a non-profit society with Government of India and a member (as a higher/professional Education Institute) of Quality Council of India(QCI) -which is an autonomous body and an accreditation authority for education & vocational training providers under the Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India -presents unique, friendly and interactive platform to get rid of all your GMP related glitches. GMP- is an essential element of industries like pharmaceutical, cosmetic, Ayurveda, biotech, homeopathic, medical device and food manufacturing. GMP in itself is the most dynamic part which witnesses frequent changes in terms of newer rules being added and older ones being renewed. Keeping self updated with current GMPs thus becomes inevitable to stay abreast with the changing industry needs and practices.
Our group of learned professionals from above mentioned sectors of the pharma and healthcare industries have put together their knowledge; know about and practical experiences in form of this GMP guide. IGMPI is moving hand in hand with technology advances and has gained recognition as stronger and better training & distance and e-learning platform provider for pharmaceutical and healthcare professionals in the aeas of GMP, Quality Assurance and Control, Pharma and healthcare Regulatory Affairs, Clinical Research, Pharmaceutical IPR and Good Laboratory Practice and Product Management. The importance of quality healthcare is known to our founders and thus numerous efforts are being made to offer friendly but effective and easy online/distance sources of GMP information, Quality Assurance and Control, Pharma and healthcare Regulatory Affairs, Clinical Research, Pharmaceutical IPR and Good Laboratory Practice in form of online seminars, distance/online courses as well as training programmes along with knowledge of worldwide affairs of the industry; in short a round-the-clock help for any information in these areas needed by anybody from around the world. Based on high standard of quality, the training programmes in Pharma and healthcare GMP, Quality Assurance and Quality Control, Regulatory Affairs, IPR, Pharma Product Management etc areas have been approved and certified by Quality Council of India.
The IGMPIs team of technology experts and other Industry advisors together pursue to make cGMP knowledge, training in the area of Pharma and healthcare manufacturing easily accessible, through this platform.
Quality Assurance and Regulatory Compliance for Pharmaceutical Product, Prof. Dr. Basavaraj K. Nanjwade, KLE University College of Pharmacy, Belgaum/Belagavi
Validation may be defined as
“ Establishing documented evidence which provides a high degree of assurance that a specific process will consistently produce a product meeting its pre-determined specifications and quality attributes.”
Dry Heat
Moist Heat
Gas (Ethylene oxide)
Radiation (Gamma or Electron)
Filtration
Others - UV, Steam and formaldehyde, hydrogen peroxide
stability The ability of a pharmaceutical product to retain its chemical, physical, microbiological and biopharmaceutical properties within specified limits throughout its shelf-life.Why is stability of a drug important?
Drug stability affects the safety and efficacy of the drug product; degradation impurities may cause a loss of efficacy and generate possible adverse effects. Therefore, achieving the chemical and physical stability of drugs is essential to ensure their quality and safety.Common factors that affect this stability include temperature, light, pH, oxidation and enzymatic degradation. Special considerations are also required when dealing with chiral molecules, deuterated internal standards and large biomolecules.
ICH Guideline Stability Testing of New Drug Substances and Product Q1A(R2).pptxTrishala Bhatt
This presentation outlines the ICH Guideline for Stability Testing of New Drug Substances and Products, Q1A(R2). It serves as a comprehensive framework for ensuring the stability of new pharmaceuticals, with a focus on the requirements for registration applications within the EC, Japan, and the United States. The guideline emphasizes a balance between a standardized approach and the flexibility to adapt to specific scientific considerations and characteristics of the materials under evaluation.
CMC, post approval regulatory affairs, etcJayeshRajput7
this document covers points such as CMC, post approval regulatory affairs, regulation for combination products, and medical devices, common technical document (CTD) and electronic common technical document (eCTD) format, industry and FDA liasion, ICH guidelines of ICH Q,S,E,M, regulatory requirements of EU, MHRA, TGA and ROW countries.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
3. It is the sum total of the
organized arrangements
with the objective of
ensuring that products
will be of the quality
required for their
intended use
QA
4. Is that part of Quality
Assurance aimed at
ensuring that products
are consistently
manufactured to a
quality appropriate to
their intended use
GMP
5. Is that part of GMP
concerned with sampling,
specification & testing,
documentation & release
procedures which ensure
that the necessary &
relevant tests are
performed & the product
is released for use only
after ascertaining it’s
quality
QC
6. QAQA andand QCQC
• QC is that part of GMP
which is concerned with
sampling,
specifications, testing
and with in the
organization,
documentation,and
release procedures
which ensure that the
necessary and relevant
tests are carried out
• QA is the sum total of
organized
arrangements made
with the object of
ensuring that product
will be of the Quality
required by their
intended use.
7. QAQA andand QCQC
• Operational
laboratory
techniques and
activities used to
fulfill the
requirement of
Quality
• All those planned
or systematic
actions necessary
to provide
adequate
confidence that a
product will satisfy
the requirements
for quality
9. Determine impurity level in
relevant batches1
Acceptance criterion = A or
B
(as appropriate)
Is
impurity also
a
degradation
product?
Is
A or B
greater than the
qualified
level?
Acceptance criterion = qualified
level
or establish new qualified level2
Estimate maximum increase in impurity
at retest date using data from relevant
accelerated and long-term stability
studies
Determine maximum likely level as:
A + increase in degradation product at
appropriate storage conditions.
(Let this = B)
YES
YES
NO
NO
ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A
NEW
DRUG SUBSTANCE
1
Relevant batches are those from development, pilot and scale-up studies.
2
Refer to ICH Guideline on Impurities in New Drug Substances
Definition: upper confidence limit = three times the standard deviation of batch analysis data
Determine mean + upper
confidence
limit for the impurity (Let this = A)
10. Does
degradation
occur during product
manufacture?
Estimate maximum increase in
degradation product at shelf life using
data from relevant accelerated and
long-term stability studies.
(Let this = D)
Determine maximum likely level as
drug substance acceptance criterion2
.
((A or B) + C + D)
Is
maximum
likely level greater
than the
qualified
level?
Estimate maximum increase in degradation
product during manufacture from relevant
batches1
. (Let this = C)
Acceptance criterion = maximum likely level.
Acceptance criterion = qualified
level
or establish new qualified level3
or new storage conditions
or reduce shelf life.
NO
NO
YES
YES
ESTABLISHING ACCEPTANCE CRITERION FOR A DEGRADATION PRODUCT IN A
NEW DRUG PRODUCT
1
Relevant batches are those from development, pilot and scale-up studies.
2
Refer to Decision Tree 1 for information regarding A and B.
3
Refer to ICH Guideline on Impurities in New Drug Products.
11. Is the drug product a solid
dosage form or liquid
containing undissolved
drug substance?
No drug substance particle
size acceptance criterion
required for solution dosage
forms.
1. Is the particle size critical to dissolution,
solubility, or bioavailability?
2. Is the particle size critical to drug product
processability?
3. Is the particle size critical to drug product stability?
4. Is the particle size critical to drug product
content uniformity?
5. Is particle size critical for maintaining
product appearance?
Set Acceptance Criterion
No Acceptance Criterion
Required
If YES to any
If NO to all
NO
YES
SETTING ACCEPTANCE CRITERIA FOR DRUG SUBSTANCE PARTICLE SIZE
DISTRIBUTION
12. INVESTIGATING THE NEED TO SET ACCEPTANCE CRITERIA FOR
POLYMORPHISM
IN DRUG SUBSTANCES AND DRUG PRODUCTS
Drug Substance
1.
2.
NO
YES
Conduct polymorphism
screen on drug substance. No further action
Can
different polymorphs
be formed?
GO TO
Characterize the forms:
e.g., - X-ray Powder
Diffraction
- DSC /
Thermoanalysis
- Microscopy
- Spectroscopy
13. INVESTIGATING THE NEED TO SET ACCEPTANCE CRITERIA FOR
POLYMORPHISM
IN DRUG SUBSTANCES AND DRUG PRODUCTS
2.
3.GO TO
NO
NO
YES
Do the
forms have
different properties?
(solubility, stability,
melting point)
Is drug
product safety,
performance or
efficacy affected?
No further test or
acceptance criterion
for drug substance
YES
Set acceptance criterion
for polymorph content
in drug substance
14. INVESTIGATING THE NEED TO SET ACCEPTANCE CRITERIA FOR
POLYMORPHISM
IN DRUG SUBSTANCES AND DRUG PRODUCTS
3.
YES
NO
NO
YES
Does
drug product
performance testing
provide adequate control if
polymorph ratio changes
(e.g., dissolution)?
Establish acceptance criteria
for the relevant performance
test(s).
Monitor polymorph form during
stability of drug product.
No need to set acceptance criteria
for polymorph change in drug
product.
Does a
change occur
which could
affect
safety or
efficacy?
Establish acceptance criteria
which are consistent with
safety and/or efficacy.
Drug Product - Solid Dosage Form or Liquid Containing Undissolved Drug Substance
Undertake the following processes only if technically possible
to measure polymorph content in the drug product.
15. ESTABLISHING IDENTITY, ASSAY AND ENANTIOMERIC IMPURITY PROCEDURES
FOR CHIRAL NEW DRUG SUBSTANCES AND NEW DRUG PRODUCTS CONTAINING
CHIRAL DRUG SUBSTANCES
YES
AND RACEMIC
Consider the need for
verifying chiral identity in
drug substance release
and/or acceptance
testing.
Is the new
drug substance
chiral1
?
Chiral identity, assay
and impurity
procedures
are not needed.
YES
AND ONE ENANTIOMER
Needed for drug substance specification:2
-chiral identity3
-chiral assay4
-enantiomeric impurity5
Needed for drug product specification6
:
-chiral assay4
-enantiomeric impurity5
NO
1
Chiral substances of natural origin are not addressed in this Guideline.
2
As with other impurities arising in and from raw materials used in drug substance synthesis, control of chiral quality could be established alternatively
by applying limits to appropriate starting materials or intermediates when justified from developmental studies. This essentially will be the case when
there are multiple chiral centers (e.g., three or more), or when control at a step prior to production of the final drug substance is desirable.
3
A chiral assay or an enantiomeric impurity procedure may be acceptable in lieu of a chiral identity procedure.
4
An achiral assay combined with a method for controlling the opposite enantiomer is acceptable in lieu of a chiral assay.
5
The level of the opposite enantiomer of the drug substance may be derived from chiral assay data or from a separate procedure.
6
Stereospecific testing of drug product may not be necessary if racemization has been demonstrated to be insignificant during drug product
manufacture and during storage of the finished dosage form.
16. MICROBIOLOGICAL QUALITY ATTRIBUTES OF DRUGSMICROBIOLOGICAL QUALITY ATTRIBUTES OF DRUGS
SUBSTANCE AND EXCIPIENTSSUBSTANCE AND EXCIPIENTS
Is the drug
substances/excipient
Capable of supporting microbial
Growth or viability
Is the drug substances/excipient
Sterile?
Does drug
substances/excipient
Synthesis/processing involve
Steps which inherently
Reduce microorganisms?
Establish microbial limit acceptance
Criteria
As per the harmonized pharmacopoeial
monograph
Are monitoring
Microorganism/indicator levels
Consistently below acceptance criteria
Levels?
Test lots on a skip-lot basis for
Microbial limits and freedom from
Compendial indicator organisms.
Test each lot for microbial limits
and freedom from compendial
indicator organisms.
Provide supporting data. Microbial
Limits acceptance criteria and
testing
May not be necessary
No further microbial limits testing or
Acceptance criteria are necessary
Establish microbial limit acceptance
criteria
As per the harmonized pharmacopeial
monograph
Does scientific evidence demonstrate that
Reducation steps result in microorganism levels
<acceptance criteria limits (and the absence of
Compendial indicator organisms)
In the drug substance/excipient?
Provide supporting data.
Microbial limits acceptace
Criteria and testing
May not be necessary
YES
YES
YES
YES
YES NO
NO
NO
NO
NO
17. 1
.
What type of drug release acceptance criteria are appropriate?
Is the dosage
form designed to produce
modified release?
YES
Establish drug release acceptance criteria.
Extended release: multiple time points
Delayed release: two stages, parallel
or sequential
Is drug solubility
at 37 ± 0.5°C high throughout
the physiological pH range?
(Dose/ solubility < 250 mL
(pH 1.2 - 6.8))
NO
Continued on next page.
Generally single-point dissolution
acceptance criteria with a lower limit
are acceptable.
Is dosage form
dissolution rapid?
(Dissolution > 80% in 15 minutes
at pH 1.2, 4.0, and 6.8)
Has a relationship been
determined between disintegration
and dissolution?
Generally disintegration acceptance
criteria with an upper time
limit are acceptable.
YES
NO
YES
YES
NO
NO
SETTING ACCEPTANCE CRITERIA FOR DRUG PRODUCT DISSOLUTION
18. 2. What specific test conditions and acceptance criteria are appropriate? [immediate release]
Does
dissolution significantly
affect bioavailability?
(e.g., have relevant developmental
batches exhibited unacceptable
bioavailability?)
Attempt to develop test conditions and acceptance
criteria which can distinguish batches
with unacceptable bioavailability.
YES
NO
YES
NO
YES
NO
Do changes in
formulation or
manufacturing variables
affect dissolution?
(Use appropriate ranges.
Evaluate dissolution
within pH 1.2 - 6.8)
Are these changes controlled
by another procedure and acceptance
criterion?
Adopt appropriate test conditions
and acceptance criteria without
regard to discriminating power, to
pass clinically acceptable batches.
Adopt test conditions and acceptance criteria
which can distinguish these changes.
Generally, single point acceptance criteria
are acceptable.
SETTING ACCEPTANCE CRITERIA FOR DRUG PRODUCT DISSOLUTION
19. 3.
YES
NO
NO
YES
YES
NO
YES
NO
Are bioavailability
data available for batches
with different drug release rates?
Is drug release independent of
in vitro test conditions?
Can an in vitro / in vivo
relationship be established?
(Modify in vitro test
conditions
if appropriate.)
Use all available stability, clinical, and
bioavailability data to establish
appropriate acceptance ranges.
Use the in vitro / in vivo
correlation, along with
appropriate batch data, to
establish acceptance ranges.
Are acceptance
ranges >20% of the
labeled content?
Provide appropriate
bioavailability data
to validate the
acceptance ranges.
Finalize acceptance
ranges.
SETTING ACCEPTANCE CRITERIA FOR DRUG PRODUCT DISSOLUTION
What are appropriate acceptance ranges? [extended release]
20. MICROBIOLOGICAL ATTRIBUTES OF NON-STERILEMICROBIOLOGICAL ATTRIBUTES OF NON-STERILE
DRUGS PRODUCTSDRUGS PRODUCTS
Does the drug product contain
Antimicrobial preservatives or possess
Inherent antimicrobial
activity
Is the drug product a dry dosage form
(e.g. solid oral or dry powder)?
Does scientific evidence demonstrate
Growth inhibitory properties of the
Drug product?
Microbial limits acceptance criteria and testing
May not be necessary
Establish preservative chemical acceptance criteria and
Perform preservative effectiveness validation of product
Containing less than or equal to the minimum specifie
Preservative concentration, or demonstrate the inherent
Antimicrobial activity of the drug product.
Establish microbial limit acceptance criteria
As per the harmonized pharmacopoeia
Monograph.
Perform microbial limits testing on a
Lot-by-lot basis.
Do production lots consistently meet
Microbial limits acceptance criteria?
Perform skip-lot testing for microbial
Limits, or provide scientific justification for
no routine microbial limits testing.
No
No
No
No
YES
YES
YES
YES
22. ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline
• Stability Testing of New Drug Substances and Products
• Stability Testing: Photostability Testing of New Drug
Substances and Products
• Stability Testing for New Dosage Forms
• Bracketing and Matrixing Designs for Stability Testing of
New Drug Substances and Products
• Evaluation for Stability Data
• Stability Data Package for Registration Applications in
Climatic Zones III and IV
• Validation of Analytical Procedures: Text and Methodology
• Impurities In New Drug Substances
23. ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline
• Impurities in New Drug Products
• Impurities: Guideline for Residual Solvents
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions on Microbiological
Examination of Non-Sterile Products: Microbial
Enumerations Tests
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions on Microbiological
Examination of Non-Sterile Products: Test for
Specified Micro-Organisms
24. ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions on Microbiological
Examination of Non-Sterile Products: Acceptance
Criteria for Pharmaceutical Preparations and
Substances for Pharmaceutical Use
• Evaluation and Recommendation of Pharmacopoeial Texts
for Use in the ICH Regions on Residue on
Ignition/Sulphated Ash
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions on Test for
Extractable Volume of Parenteral Preparations
25. ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions on Test for
Particulate Contamination: Sub-Visible Particles
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions on Disintegration
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions on Uniformity of
Dosage Units
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Region on Dissolution Test
26. ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions on Sterility Test
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions onTablet Friability
• Evaluation and Recommendation of Pharmacopoeial
Texts for Use in the ICH Regions on Polyacrylamide
Gel Electrophoresis
• Viral Safety Evaluation of Biotechnology Products
Derived from Cell Lines of Human or Animal Origin
27. ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline
• Quality of Biotechnological Products: Analysis of the
Expression Construct in Cells used for Production of r-DNA
Derived Protein Products
• Quality of Biotechnological Products: Stability Testing of
Biotechnological/Biological Products
• Derivation and Characterisation of Cell Substrates Used for
Production of Biotechnological/Biological Products
• Comparability of Biotechnological/Biological Products
Subject to Changes in their Manufacturing Process
• Specifications: Test Procedures and Acceptance Criteria for
New Drug Substances and New Drug Products: Chemical
Substances
28. ICH Harmonised Tripartite GuidelineICH Harmonised Tripartite Guideline
• Specifications: Test Procedures and Acceptance
Criteria for Biotechnological/Biological Products
• Good Manufacturing Practice Guide for Active
Pharmaceutical Ingredients
• Pharmaceutical Development
• Quality Risk Management
• Pharmaceutical Quality System
• Quality Implementation Working Group
30. How to write Standard OperatingHow to write Standard Operating
ProcedureProcedure
• SOP describes standard SOP format
that you can use immediately for
your quality procedure.
• SOP has instructions on how to write
a formal operating procedure for
your systems which your people can
follow everyday.
31. All Documents-Classifications,All Documents-Classifications,
Definition and Approval MatrixDefinition and Approval Matrix
• In this SOP you will find all type of quality
and Technical/Master file documents to
build up a good quality management
system for your manufacturing sites,
definition of documents, their
classification, approval requirements and
retention requirements.
• This procedure has schematic diagrams for
your understanding of how different types
of documents are prepared and stored in a
typical documentation.
32. Quality Documentation ManagementQuality Documentation Management
and Change Controland Change Control
• This SOP describes how to generate new
quality documents or change control of
existing documents, review of quality
documents, satellite file management, role
of document author, approver, document
control officer and satellite file
administrator.
• In this SOP you will also find numbering
systems of different quality documents like
audit files, SOP’s, forms, manuals, training
files, QA agreements, project files etc and
their effective archiving system.
33. Documentation Rule for GMPDocumentation Rule for GMP
DocumentsDocuments
• This SOP describes the principles to
be followed in GMP documents, entry
of data and information, signature
requirements and correction
technique of incorrectly entered data
or information.
34. Quality Documentation-Control,Quality Documentation-Control,
Tracking and DistributionTracking and Distribution
• In this SOP you will find mainly the role of
document control officer during the initiation,
creation, circulation and approval of new quality
related documents.
• It also describes the procedure of modification
and review of existing document using a
documentation database.
• Management of existing and superseded
documents is also a art of this procedure.
• You will see all the forms referred during the
instruction are attached at the end of the
procedure.
35. Preparation, Maintenance andPreparation, Maintenance and
Change Control of Master DocumentsChange Control of Master Documents
• This SOP particularly focused on the management
of master file documents like specifications,
control methods, raw materials, finished goods
and packaging specification and test reports,
formulation, stability files etc required to
generate during the product registration in the
market.
• This SOP gives instruction on their creation,
change control, numbering system, approval
requirements and maintenance in a simple
master file database.
• You will see all the forms referred during the
instruction are attached at the end of the
procedure.
36. Deviation Report SystemDeviation Report System
• It is a regulatory requirement to capture all sorts
of deviations evolves in your systems in order to
maintain the continuous improvement to your
processes and systems.
• This SOP describes how to categorize the
deviations between production, audit, quality
improvements, technical deviations, customer
complaints and environmental, health and safety
deviations.
• It describes the management responsibilities of
initiating deviation, capture data, analysis,
investigation, determination of assignable causes,
generation of management report and initiatives
to be taken on corrective and preventative
actions.
37. Shelf Life of ProductShelf Life of Product
• This simple SOP describes the
meaning of shelf life and provides on
how to interpret shelf lives and
storage conditions for your raw
materials from the Certificate of
Analysis, determining expiry date for
your finished products by use of raw
material date of manufacturing and
their shelf lives.
38. Vendor Selection and EvaluationVendor Selection and Evaluation
• This SOP describes the procedure to be
followed during the vendor assessment
and vendor evaluation for purchasing of
raw materials, critical and non critical
packaging components, laboratory
supplies, engineering supplies and
imported finished goods from the vendor.
• These instructions are essential for
approving prospective vendor.
39. Vendor CertificationVendor Certification
• This procedure aim to describe the process
by which a vendor may be certified to
supply materials or services.
• This procedure applies to vendors that
supply a material or service to be used at
any stage of manufacture by operations.
• Here you will get the roles of each
department in the process to certify an
approved vendor.
40. Product Complaint ProcedureProduct Complaint Procedure
• This procedure covers the receipt, logging,
evaluation, investigation and reporting system of
all complaints received from customers for the
marketed products.
• This SOP contains step by step instruction to be
followed in the customer complaint management
like numbering of complaint, registration,
evaluation of complaints, determination of
assignable cause for the complaint deviation,
implementation of corrective and preventive
actions, trending of complaints and handling of
counterfeit products.
41. Annual Product ReviewAnnual Product Review
• This procedure provides a guideline
to annual product review which is
required to be performed for each
product produced for the commercial
market to evaluate data, trends and
to identify any preventative or
corrective action that would lead to
product quality improvements and
report them to management.
42. Rework ProcedureRework Procedure
• This SOP contains the step by step instruction to
be followed when the rework of an in-process or
completed finished good is required.
• This SOP covers the reworks of in-process
manufactured goods where new batch number is
introduced for the reworked part and rework of
manufactured finished good keeping the same
batch number.
• This SOP also describes how to create rework
protocols for each individual case.
43. Authorized PersonAuthorized Person
• This simple procedure describes the
accreditation, accountabilities and
responsibilities of an Authorized
person, responsible for release of
finished goods for sale.
44. Product Identification andProduct Identification and
TraceabilityTraceability
• The purpose of this SOP is to define the
method used for the identification of all
contributing materials that could affect
product quality and to ensure their full
traceability.
• Here you will find instruction on all the
records and documents used for the
identification and traceability of incoming
raw materials and out going finished
goods.
45. AuditsAudits
• This SOP describes the process of
planning, performing, reporting and
follow-up of different audits for your
systems like Internal Quality audit, Vendor
audit, Environmental Health and Safety
(EHS) audit, EHS workplace inspection,
Housekeeping audit.
• This SOP also describes the process to be
followed by manufacturing personnel
during an audit from a Regulatory
authority.
46. Example-Checklist for Batch DocumentationExample-Checklist for Batch Documentation
• This SOP describes the identification of all
documentation relevant to a production
process in the form of “Batch
Documentation Checklists” and to ensure
their collection by completion of the
checklists by Authorized Persons.
• This procedure is based on an example of
tablet packaging process described in the
‘Manufacturing’ category.
47. Evaluation of Batch DocumentationEvaluation of Batch Documentation
and Release for Saleand Release for Sale
• This procedure describes the process of
collection, evaluation and record of batch
related document generated during the
production of a batch before an authorized
person can release the batch for sale.
• This procedure is based on an example of
tablet packaging process described in the
‘Manufacturing’ category.
48. GMP TrainingGMP Training
• This SOP describes how to design
and deliver GMP related training for
your manufacturing staffs, training
assessment design, recording of
assessment and preparation of
training reports.
49. How to Write Training MaterialsHow to Write Training Materials
• This simple SOP contains instructions
on how to write training materials,
identification of training
requirements, available resources,
preparation of training aid checklists
for your manufacturing staffs.
50. House Keeping Audit ProcedureHouse Keeping Audit Procedure
• This SOP describes the requirements, checklists
and reporting procedure on housekeeping audits.
• Individual checklist forms are attached at end of
the procedure for different areas like process,
laboratory, engineering stores, warehouses.
• This procedure also describes the handling of
non-compliance found during the housekeeping
audits.
51. Management and Control of Contract WorkManagement and Control of Contract Work
• The procedure describes the
management and control of contract
work provided by the contractors for
packaging and finished products for
your company as well as control of
contract works done by your
company on behalf of others.
52. Criteria for Sourcing of RM, CriticalCriteria for Sourcing of RM, Critical
Packaging Components and ImportedPackaging Components and Imported
Finishing GoodsFinishing Goods
• The purpose of this SOP is to describe the process
for approval of an external vendor/manufacturer
supplying products to your company.
• It covers raw materials (including bulk products
for subsidiaries and contract manufacturers),
critical packaging components in contact with
product and imported finished goods.
• The SOP also references affiliated documentation
detailing the scope of active materials used and
the approved manufacturers of these materials.
53. Quality Concern InvestigationQuality Concern Investigation
ProcessProcess
• This procedure contains instruction to be followed
when conducting Investigations and to raise and
assess Deviation Report when an investigation or
incident Investigation occurs.
• This procedure is to be used in conjunction with
SOP, which covers the approval and follow-up
activities associated with a Deviation Report.
• Here you will find collection of information for an
incident or a deviation, steps to be followed for a
cross functional investigation, reporting and
implementing of the outcomes of investigation.
55. Retest Dating of Raw MaterialsRetest Dating of Raw Materials
• The purpose of this procedure is to
describe how to run the expired stock
report; to describe how to define the
requirements for the retesting and
assignment of storage period for active
ingredients, excipients and raw materials;
to instruct retesting procedure and to
determine the status of a finished goods
batch with a shorter shelf life.
56. Calibration Policies for LaboratoryCalibration Policies for Laboratory
InstrumentsInstruments
• This SOP describes the calibration polices
of laboratory instruments/equipments.
• It describes labeling and security
requirements of laboratory
instruments/equipments.
• This SOP also describes the investigational
steps to be required in the case of failed
calibration
57. Archiving Laboratory DocumentationArchiving Laboratory Documentation
• This procedure describes retention and
disposal procedures of laboratory
documentation, general laboratory
documentation system that includes
handling of rejected raw material and
finished product reports, finished goods
certificate of analysis, finished goods
register, raw material certificate of
analysis, register, trend cards, procedure
for long term document retention.
58. Management of ReferenceManagement of Reference
SubstancesSubstances
• This SOP describes the ordering
referencing, storing, coding, use and
general register maintenance of primary
and impurity reference substances,
primary reagent reference solutions,
secondary raw material reference
substance, assay testing procedure of
secondary raw material reference
substance, use of secondary raw material
reference substance in the laboratory
routine analysis, determination of expiry
date and re-test date of reference
substances.
59. Laboratory WorkbookLaboratory Workbook
• This SOP describes types of laboratory
workbooks, general and GMP requirements
of using workbooks, analytical data entry
in the workbook, formatting of laboratory
workbooks for routine testing,
experiments and trials, workbook
retention policy, instruction on data entry
for incomplete experiments and additional
data.
60. Creation of Certificate of AnalysisCreation of Certificate of Analysis
• The purpose of this procedure is to
define the content and format of a
Certificate of Analysis (C/A) and
Certificate of Manufacture (C/M) and
to provide guidance for issuing a
Certificate of Analysis or Certificate
of Manufacture and to locate the
appropriate data required for this
task.
61. Managing Analytical ReagentsManaging Analytical Reagents
• This procedure identifies the need for all
analytical reagents and solutions prepared
from the reagents, to have an assigned
expiry date and storage conditions
recorded on the label.
• Here you will find the procedure for
purchase and management of analytical
reagents and laboratory prepared
reagents.
62. Laboratory Waste ManagementLaboratory Waste Management
• This simple procedure describes how
to dispose off laboratory generated
wastes of toxic, explosive, flammable,
corrosive, oxidizing and biologically
damaging natures.
63. Retention Samples-LaboratoryRetention Samples-Laboratory
• The purpose of this SOP is to
describe the finished good and raw
material sample retention
procedures, products manufacture
and/or received onsite and/or
chemically tested by the laboratory.
64. Laboratory Supplier ApprovalLaboratory Supplier Approval
• In this simple SOP you will find the
procedure for approving laboratory
suppliers and criteria for the
purchase of equipment,
instrumentation, consumables,
durables and glassware for the
laboratory.
65. Laboratory Results-Out of SpecificationLaboratory Results-Out of Specification
InvestigationInvestigation
• This procedure describes the actions to be taken
by an analyst in the event the result of a test
does not conform to raw material/components or
finished products specifications for physical and
chemical tests.
• An out of specification (OOS) result does not
necessarily mean the batch under investigation
fails and shall be rejected.
• The OOS result shall be investigated and the
findings of the investigation, including re-test
results shall be interpreted to evaluate the batch
and reach a decision regarding release or
rejection.
66. Raw Materials-Laboratory TestingRaw Materials-Laboratory Testing
and Documentationand Documentation
• This SOP describes the procedure for
sampling, location, pre-testing,
testing and documentation of all raw
materials and components subject to
test, out of specification results,
microbiological tests and release
procedure for passed raw materials
and components.
67. Finished Goods-Laboratory Testing andFinished Goods-Laboratory Testing and
DocumentationDocumentation
• This SOP describes the procedure for
sampling, location, pre-testing,
testing and documentation of all
finished products subject to test,
reagents and standards to be used
for analysis, management of out of
specification results, microbiological
tests and release procedure for
passed finished goods.
68. Preparation and Maintenance ofPreparation and Maintenance of
Stability Protocols (Pharmaceuticals)Stability Protocols (Pharmaceuticals)
• This procedure describes the preparation and
management of stability protocols for marketed
products.
• This procedure is applicable to all protocols for
stability studies on commercial products.
• The responsibility of the commercial Site stability
manager for creating and maintaining protocols
that are required for studies that came as a result
of validation or process deviation.
69. Stability and Trial Testing ProcedureStability and Trial Testing Procedure
(Pharmaceuticals)(Pharmaceuticals)
• To describes the steps necessary to ensure the
effective control of stability and trial testing
programs of new and existing products.
• This procedure is focused on setting up of
stability programs, testing, reporting, general
sampling procedure for stability programs, data
generation and analysis, annual maintenance of
stability, new product stability procedure,
procedure for in-house trials, reporting and
interpretation of trials and conclusion of the trail
program.